- Home
- NXGL vs CARA Comparison
NXGL vs CARA Comparison
Compare NXGL & CARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXGL
- CARA
- Stock Information
- Founded
- NXGL 1997
- CARA 2004
- Country
- NXGL United States
- CARA United States
- Employees
- NXGL N/A
- CARA N/A
- Industry
- NXGL Medical/Dental Instruments
- CARA Biotechnology: Pharmaceutical Preparations
- Sector
- NXGL Health Care
- CARA Health Care
- Exchange
- NXGL Nasdaq
- CARA Nasdaq
- Market Cap
- NXGL 23.8M
- CARA 23.1M
- IPO Year
- NXGL 2021
- CARA 2014
- Fundamental
- Price
- NXGL $3.32
- CARA $4.97
- Analyst Decision
- NXGL
- CARA Hold
- Analyst Count
- NXGL 0
- CARA 3
- Target Price
- NXGL N/A
- CARA $12.00
- AVG Volume (30 Days)
- NXGL 66.5K
- CARA 25.1K
- Earning Date
- NXGL 03-27-2025
- CARA 03-03-2025
- Dividend Yield
- NXGL N/A
- CARA N/A
- EPS Growth
- NXGL N/A
- CARA N/A
- EPS
- NXGL N/A
- CARA N/A
- Revenue
- NXGL $6,729,000.00
- CARA $8,686,000.00
- Revenue This Year
- NXGL $115.48
- CARA N/A
- Revenue Next Year
- NXGL $49.27
- CARA N/A
- P/E Ratio
- NXGL N/A
- CARA N/A
- Revenue Growth
- NXGL 90.57
- CARA N/A
- 52 Week Low
- NXGL $1.84
- CARA $2.71
- 52 Week High
- NXGL $5.10
- CARA $13.80
- Technical
- Relative Strength Index (RSI)
- NXGL 44.29
- CARA 49.66
- Support Level
- NXGL $3.06
- CARA $4.94
- Resistance Level
- NXGL $3.66
- CARA $5.73
- Average True Range (ATR)
- NXGL 0.26
- CARA 0.30
- MACD
- NXGL 0.02
- CARA -0.04
- Stochastic Oscillator
- NXGL 35.37
- CARA 30.28
About NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.
About CARA Cara Therapeutics Inc.
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.